On January 9, 2018 4SC AG (4SC, FSE Prime Standard: VSC) reported its participation at upcoming conferences and investor events. 4SC’s management will be available for one-on-one meetings at these events (Press release, 4SC, JAN 9, 2018, View Source [SID1234523022]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

4th annual Biotech and Money / Medtech and Money World Congress
5 February 2018
etc.venues
London, United Kingdom

BioCapital Europe 2018
6 February 2018
Sofitel Legend Amsterdam The Grand
Amsterdam, The Netherlands

Non Deal Roadshow: Amsterdam
7 February 2018
Amsterdam, The Netherlands

2018 BIO CEO & Investor Conference
12 – 13 February 2018
New York Marriott Marquis
New York, USA

Non Deal Roadshow: New York
14 February 2018
New York, USA

Non Deal Roadshow: Scandinavia
19 – 20 February 2018
Scandinavia

12th ODDO BHF German Conference (micro, small & mid cap)
21 – 22 February 2018
The Westin Grand Hotel
Frankfurt am Main, Germany

Non Deal Roadshow: Zurich
28 February 2018
Zurich, Switzerland

Non Deal Roadshow: Geneva
1 March 2018
Geneva, Switzerland

Non Deal Roadshow: Luxembourg / Belgium
16 March 2018
Luxembourg / Belgium

Munich Stock Exchange Day 2018
17 March 2018
MOC Veranstaltungscenter
Munich, Germany

On January 8, 2018 Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and licensing agreement with TESARO, Inc., an oncology-focused biopharmaceutical company, to develop novel multi-specific antibodies for up to six undisclosed oncology targets (Press release, TeneoBio, JAN 8, 2018, View Source [SID1234585553]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Teneobio will generate product candidates using its proprietary UniRat transgenic human antibody ‘heavy-chain only’ rodent platform and its state-of-the-art sequence-based discovery engine, TeneoSeek. TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.

Teneobio Inc. will receive an upfront of $10 million and is eligible for research fees and up to $50M in development milestones per product. Teneobio would also receive royalties on world–wide net sales of each multi-specific product. Additional terms of the agreement were not disclosed.

Roland Buelow, CEO of Teneobio, added, "We are excited to embark on a productive research collaboration with TESARO. The rapid, sequence-based discovery of UniRat-derived modular human variable heavy-chain antibody domains (UniDabs), enables the assembly of robust, optimized multi-specific therapeutics with excellent manufacturability. Complementing our internal pipeline, our strategic alliance with TESARO further leverages the bandwidth and efficiency of Teneobio’s state-of-the-art discovery platforms to advance specific biotherapeutics to the clinic. TESARO’s track record and focus on immuno-oncology are a great match to our interests and our goal to address unmet medical needs with novel mechanisms of action that are now afforded by breakthrough multi-specifics."

"Single domain antibodies have emerged as a leading platform that enables targeted immune activation," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "This strategic research collaboration with Teneobio will allow us to develop biologic drug candidates with novel mechanisms of action. We look forward to working with the Teneobio team, which has a strong track record of success in designing biologic drug candidates."

On January 8, 2018 STORM Therapeutics, the leading drug discovery company focused on small molecule therapies modulating RNA modifying enzymes, reported that it has raised an additional £4 million of funding from Taiho Ventures, LLC the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd (Press release, STORM Therapeutics, JAN 8, 2018, View Source [SID1234561046]). This is an addition to the £12 million Series A Financing announced in June 2016. Taiho Ventures joins the existing blue chip investor syndicate of Merck Ventures, Cambridge Innovation Capital, Pfizer Venture Investments and Touchstone Innovations with an equal size of investment. Sakae Asanuma, President of Taiho Ventures, joins STORM Therapeutics’ Board of Directors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following encouraging progress to date, the financing will enable STORM Therapeutics to expand and accelerate its pipeline, pursue emerging therapeutic opportunities, and build a broader drug discovery platform encompassing new drug targets from additional academic collaborators and its scientific founders.

Commenting on the fundraising, Keith Blundy, CEO of STORM Therapeutics, said: "We are pleased to welcome Taiho Ventures to our existing investor syndicate. This extended investment represents further validation and support of our strategy to harness the power of RNA epigenetics as a new area of important biology. As the first company tackling disease through modulating RNA modifying enzymes, we believe we are well positioned to build a world leading company."
Sakae Asanuma, President of Taiho Ventures, added: "We are excited to join this experienced management team and investor syndicate to help STORM Therapeutics fulfil its ambition to become the leading therapeutics company in RNA epigenetic modulation. Our strategy is to invest globally in companies that discover and develop innovative first-in-class therapeutic products that demonstrate a clear potential to benefit cancer patients, and as our first investment in Europe we believe that STORM’s innovative approach has the potential to significantly improve the way the world treats cancer."

On January 8, 2018 Oncoceutics, Inc. reported that the Japanese Patent Office (JPO) has issued Japanese Patent No. 6132833 for the use of ONC201 to treat all cancers or patients having a risk of cancer, including brain, colon, breast, colorectal cancers, and glioblastoma (Press release, Oncoceutics, JAN 8, 2018, https://oncoceutics.com/oncoceutics-extends-ip-coverage-japan-new-patent-covering-cancers/ [SID1234558374]). The claims issued also include the use of ONC201 when administered in conjunction with another anticancer agent and 25 routes of administration, including oral administration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is the first patent issued outside the United States covering ONC201. This patent, combined with issued patents for ONC201 formulation and use in combination with other therapies, as well as FDA regulatory designations that ONC201 has received, provides ONC201 with a robust suite of intellectual property.

ONC201, a member of the imipridone family, has demonstrated anti-cancer activity and safety in preclinical models and ongoing clinical trials, including a trial for various solid and liquid tumors. Oncoceutics has also received patents covering its next generation of imipridones, namely ONC206 and ONC212.

"We are delighted that the Japanese Patent Office has recognized these indications as novel uses of ONC201 and granted these broad patent protections in such an important market," said Martin Stogniew, Ph.D., Chief Development Officer of Oncoceutics. "The company’s current patent estate gives Oncoceutics more than 15 years of patent protection for the vast majority of human cancers, including tumor types where ONC201 is currently in Phase II trials."

On January 8, 2018 Critical Outcome Technologies Inc. (TSX VENTURE:COT)(OTCQB:COTQF) ("COTI" or the "Company"), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported a name change from "Critical Outcome Technologies Inc." to "Cotinga Pharmaceuticals Inc (Press release, Critical Outcome Technologies, JAN 8, 2018, View Source [SID1234533160])." The effective date of the name change, approved by shareholders in December 2017, is expected to be January 10, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This new brand signifies the Company’s evolution from a technology-driven company to a clinical-stage pharmaceutical company. The name is derived from the Cotingas, one of the world’s largest and most diverse bird species, and symbolizes the Company’s focus on developing innovative therapies to treat a wide spectrum of cancers.

"We are excited to officially introduce Cotinga Pharmaceuticals," said Alison Silva, President & CEO. "After a close review of the business, we have launched a new brand that reaffirms our identity, recognizes our achievements in the clinic, and underscores our continued commitment to develop therapeutics for patients suffering from various cancers. We have made considerable progress advancing our pipeline of targeted therapies to date, and we look forward to building on this progress in the year ahead as we continue the Phase 1 trial of our lead compound, COTI-2, in head and neck squamous cell carcinoma (HNSCC) and prepare our second compound, COTI-219, for an investigational new drug (IND) submission."